Published: 2022-02-28

Survey of effective factors in slow flow and no reflow in primary percutaneous coronary intervention patients

Behzad Babapoor, Saeid Sadeghieh-Ahari, Mehdi Sadeghi Hariri, Bita Shahbazzadegan


Background: The phenomenon of no reflow is a phenomenon that after angioplasty and the successful insertion of the stent, the blood flow rate is reduced again in the coronary arteries and there is no mechanical obstruction. The slow flow phenomenon is an angiogram that is associated with delayed progression of contrast media during coronary artery during angiography in the absence of coronary stenosis. The aim of this study was to investigate the prevalence and factors affecting these phenomenons in Primary percutaneous coronary intervention (PCI) patients.

Methods: This cross-sectional study was performed. The statistical population of the patients is 340 people who were under the Primary PCI. After the patients 'data, information was collected through a questionnaire and patients' records.

Results: 48 patients entered the PCI process more than 90 minutes after admission to hospital. The highest frequency is related to anterior MI and LAD was the most frequency based on type of vessel involvement, 12 of them died and 17.1% of patients had no reflow and 12.9% of patients had slow flow. The mean diameter of stents in patients was 2.98 and the mean balloon diameter in patients was 2.01 and there is a significant relation between stent diameter and balloon diameter with slow flow and no reflow (p<0.05).

Conclusions: The results of this study showed that the prevalence of slow flow and no reflow after primary PCI in patients with heart attacks were at a high level with 12.9% for slow flow and 17.1% for no reflow.


Initial angioplasty, No reflow, Slow flow

Full Text:



Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. Harrison's principles of internal medicine, 19ed. New York, Mcgraw-hill; 2015.

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. New England J Med. 2005;352:1685-95.

Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78:1157-66.

Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation. 2002;105:656–62.

Kloner RA, Ganote CE, Jennings RB. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54:1496-508.

Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J. 2001;22:729-39.

Beltrame JF, Limaye SB, Horowitz JD. The coronary slow flow phenomenon–a new coronary microvascular disorder. Cardiology. 2002;97:197-202

Beltrame JF, Limaye SB, Wuttke RD, Horowitz JD. Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon. Am Heart J. 2003;146:84-90.

Beltrame JF, Turner SP, Leslie SL, Solomon P, Freedman SB, Horowitz JD. The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon. J Am Coll Cardiol. 2004;44:57-62.

Gupta S, Gupta MM. No Reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart J. 2016;68:539-51.

Mazhar J, Mashicharan M, Farshid A. Predictors and outcome of no-reflow post primary percutaneous coronary intervention for ST elevation myocardial infarction. Int J Cardiol Heart Vasc. 2016;10:8-12.

Kaul S. The “No Reflow” phenomenon following acute myocardial infarction: mechanisms and treatment options. J Cardiology. 2014;64:77-85.

Yilmaz H, Demir I, Uyar Z. Clinical and coronary angiographic characteristics of patients with coronary slow flow. Actacardiologica. 2008;63:579-84

Biranvand M, Assad PM. Dyslipidemia and coronary artery disease. J Shahid Beheshti University of Medical Sciences. 2005;54:384-8.

Sakuma I, Kishimoto N, Oyama N, Saijo Y, Nawate S, Souma T. Low high-density lipoprotein cholesterol, hypertension, diabetes, but not high low-density lipoprotein cholesterol as predictors of acute coronary syndrome in Northern Area of Japan: A case-control study. JACC. 2004;13:1047-180.

Hammoudeh AJ, Al-Tarawneh H, Elharassis A, Haddad J, Mahadeen Z, Badran N. Prevalence of conventional risk factors in Jordanians with coronary heart disease: The Jordan Hyperlipidemia and Related Targets Study (JoHARTS). Int J Cardiol 2005;24:21-8.

Umesh N, Khot M. prevalence of conventional risk factors with coronary heart disease. JAMA. 2003;290:898-904.

Deepak L, Gabril P. International prevalence, recognition and treatemtnt of cardiovascular risk factors. JAMA 2006;295:180-9.

Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries--a new angiographic finding. Am Heart J. 1972;84:66-71.

Beltrame JF, Limaye SB, Wuttke RD, Horowitz JD. Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon. Am Heart J. 2003;146:84-90.

Li JJ, Xu B, Li ZC, Qian J, Wei BQ. Is slow coronary flow associated with inflammation? Me Hypotheses 2006;66:504-8.

Wozakowska-Kaplon B, Niedziela J, Krzyzak P, Stec S. Clinical manifestations of slow coronary flow from acute coronary syndrome to serious arrhythmias. Cardiol J. 2009;16:462-8.

Habilu Y, Abdullah D, Yasin T, Atilla I, Salaheddin A, İbrahim E. Lack of association between the glu298asp polymorphism of endothelial nitric oxide synthase and slow coronary flow. J Am Coll Cardiol. 2013;62:54-5.

Mosseri M, Yarom R, Gotsman MS, Hasin Y. Histologic evidence for small-vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation. 1986;74:964-72.

Gori T, Fineschi M. Two coronary “orphan” diseases in search of clinical consideration: coronary syndromes x and y. Cardiovasc Ther. 2012;30:58-65.

Crea F, Lanza GA. Angina pectoris and normal coronary arteries: cardiac syndrome. Heart. 2004;90:457-63.

Singh S, Kothari S, Bahl V. Coronary slow flow phenomenon: an angiographic curiosity. Indian Heart J. 2004;56:613-7.

Diver DJ, Bier JD, Ferreira PE, Sharaf BL, McCabe C, Thompson B. Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial). Am J Cardio. 1994;74:531-7.

Sezgin AT, Sigirci A, Barutcu I, Topal E, Sezgin N, Ozdemir R. Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis. 2003;14:155-61

Erdogan D, Caliskan M, Gullu H, Sezgin AT, Yildirir A, Muderrisoglu H. Coronary flow reserve is impaired in patients with slow coronary flow. Atherosclerosis. 2007;191:168-74.

Abbo KM, Dooris M, Glazier S. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol. 1995;75:778- 82.

Morishima I, Sone T, Mokuno S. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J. 1995;130:239-43.

Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54:1496-508.

Reffelmann T, Kloner RA. Microvascular alterations after temporary coronary artery occlusion: the no-reflow phenomenon. J Cardiovasc Pharmacol Ther. 2004;9:163-72.

Olafsson B, Forman MB, Puett DW. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no reflow phenomenon. Circulation. 1987;76:1135-45.

Paik GY, Caputo RP, Nunez BD. Thrombus contains solu ble factors which decrease blood flow in swine coronary arteries through a nitrous oxide-dependent pathway. J Am Coll Cardiol. 1994;23:64.

Hong YJ, Jenog MH, Choi YH. Impact of plaque components on No-Reflow phenomenon after stent deployment in patients with acute coronary syndrome: virtual histology- intravascular ultrasound analysis. Europ Heart J. 2009;10:34-41.

Matsumoto H, Inone N, Takaoka H. Depletion of antioxidants is associated with No-Reflow phenomenon in acute myocardial infarction. Clin Cardiol. 2004;27:466-70.

Brosh D, Assali AR, Mager A. Effect of no-reflow during Primary percutaneous coronary intervention for acute myocardial infarction on six month mortality. Am J Cardiol. 2007;99:442-5.

Zalewski J, Undas A, Godlewski J. No reflow phenomenon after acute myocardial infarction is associated with reduced clot permeability and susceptibility to lysis. Arterioscler Thromb Vasc Biol. 2007;27:2258-65.